Pioneering Effective Delivery Solutions: Breaking Barriers in Targeted Cancer Therapy
Click on the animation above to see how our lead candidate therapeutic works
|
Delivering Where it
|
TransCode Therapeutics believes it has overcome the delivery
challenges of targeted delivery of therapeutics to cancer cells
Lead Therapeutic Candidate, TTX-MC138 targets miRNA-10b widely considered
the master regulator of cancer progression in 19+ tumor indications
A small, non-coding microRNA called miRNA-10b, is shown to be the master regulator of metastasis in a range of solid tumors
Metastatic tumor cells are better equipped to safely travel to other parts of the body and develop metastases in organs different from the organ of origin
|
Cells in the primary tumor are known to upregulate miRNA-10b which allows metastatic cells to develop, detach, and migrate
TransCode’s TTX platform has the potential to treat a variety of
tumor indications through effective delivery and targeting |